CY2617B2 - Use of mometasone furoate for treating airway passage and lung diseases - Google Patents

Use of mometasone furoate for treating airway passage and lung diseases

Info

Publication number
CY2617B2
CY2617B2 CY1100007A CY1100007A CY2617B2 CY 2617 B2 CY2617 B2 CY 2617B2 CY 1100007 A CY1100007 A CY 1100007A CY 1100007 A CY1100007 A CY 1100007A CY 2617 B2 CY2617 B2 CY 2617B2
Authority
CY
Cyprus
Prior art keywords
mometasone furoate
lung diseases
airway passage
treating airway
allergic
Prior art date
Application number
CY1100007A
Other languages
English (en)
Inventor
Joel A Sequeira
Keith B Nolop
Nagamani Nagabhushan
Francis M Cuss
Imtiaz A Chaudry
James E Patrick
Mitchell Cayen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22692858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2617(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CY2617B2 publication Critical patent/CY2617B2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY1100007A 1994-01-27 2011-10-27 Use of mometasone furoate for treating airway passage and lung diseases CY2617B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18837294A 1994-01-27 1994-01-27
EP01119613A EP1174138B1 (en) 1994-01-27 1995-01-26 Use of mometasone furoate for treating airway passage and lung diseases

Publications (1)

Publication Number Publication Date
CY2617B2 true CY2617B2 (en) 2012-05-23

Family

ID=22692858

Family Applications (2)

Application Number Title Priority Date Filing Date
CY1100006A CY2616B2 (en) 1994-01-27 2011-10-27 Use of mometasone furoate for treating airway passage and lung diseases
CY1100007A CY2617B2 (en) 1994-01-27 2011-10-27 Use of mometasone furoate for treating airway passage and lung diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY1100006A CY2616B2 (en) 1994-01-27 2011-10-27 Use of mometasone furoate for treating airway passage and lung diseases

Country Status (29)

Country Link
EP (6) EP0740550B1 (xx)
JP (6) JP3480736B2 (xx)
KR (1) KR100234864B1 (xx)
CN (4) CN101156860A (xx)
AT (5) ATE518520T1 (xx)
AU (1) AU691880B2 (xx)
CA (1) CA2182086C (xx)
CO (1) CO4340692A1 (xx)
CY (2) CY2616B2 (xx)
CZ (1) CZ219196A3 (xx)
DE (1) DE69526425T2 (xx)
DK (3) DK1174138T3 (xx)
ES (3) ES2368827T3 (xx)
FI (2) FI122395B (xx)
HK (5) HK1040912A1 (xx)
HU (1) HU227837B1 (xx)
IL (1) IL112459A (xx)
MX (1) MX9602246A (xx)
MY (1) MY114665A (xx)
NO (2) NO314535B1 (xx)
NZ (1) NZ279979A (xx)
PE (1) PE44995A1 (xx)
PL (1) PL315575A1 (xx)
PT (3) PT740550E (xx)
SG (1) SG47387A1 (xx)
SK (1) SK283338B6 (xx)
TW (1) TW329387B (xx)
WO (1) WO1995020393A1 (xx)
ZA (1) ZA95637B (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
DE69731473T2 (de) * 1996-05-09 2005-10-27 Amrad Operations Pty. Ltd., Richmond Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
KR100316358B1 (ko) * 1996-08-29 2001-12-12 둘락 노먼 씨. 클로로플루오로카본 비함유 모메타손 푸로에이트 에어로졸 제형
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP2036544B1 (en) * 1997-03-20 2016-12-28 Merck Sharp & Dohme Corp. Dosage form of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
WO1999018971A1 (en) * 1997-10-09 1999-04-22 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
ES2284531T3 (es) * 1999-10-08 2007-11-16 Schering Corporation Tratamiento nasal topico usando desloratadina y furoato de mometasona.
AR029189A1 (es) * 1999-11-02 2003-06-18 Smithkline Beecham Corp Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
ES2305029T3 (es) 2000-12-22 2008-11-01 Nippon Shinyaku Co., Ltd. Agente preventivo/terapeutico para enfermedades inflamatorias del tracto respiratorio.
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
WO2005037245A2 (en) * 2003-10-21 2005-04-28 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
JP2007509941A (ja) * 2003-10-28 2007-04-19 グラクソ　グループ　リミテッド ラクトース無水物を用いる吸入医薬製剤およびその投与方法
MXPA06008240A (es) * 2004-01-21 2006-08-31 Schering Corp Metodos de tratamiento.
JP4893999B2 (ja) * 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
EP3354276B1 (en) 2007-11-13 2020-01-01 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
WO2010013240A1 (en) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
EP3834819A1 (en) * 2008-08-20 2021-06-16 The Regents of the University of California Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
EP2349206A2 (en) * 2008-10-10 2011-08-03 Schering Corporation Corticosteroid compositions and methods of treatments thereof
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN105792828A (zh) 2013-10-04 2016-07-20 格兰马克药品有限公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN107260665B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种吸入用糠酸莫米松混悬液组合物
CN111787954B (zh) 2018-02-23 2023-09-05 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
CN113933415B (zh) * 2021-09-30 2023-03-24 北京阳光德美医药科技有限公司 一种hplc-ms/ms测定人血浆中糠酸酯浓度的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4972830A (en) 1985-07-31 1990-11-27 Vortran Medical Technology, Inc. Inhalation device and method
US4873335A (en) 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
US4910192A (en) * 1987-12-04 1990-03-20 Sri International Topically active steroidal anti-inflammatory agents
ATE224748T1 (de) * 1989-04-28 2002-10-15 Riker Laboratories Inc Inhalationsvorrichtung für trockenpulver
WO1991014422A1 (en) * 1990-03-23 1991-10-03 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
HU213401B (en) * 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it
ATE146970T1 (de) * 1990-10-16 1997-01-15 John Lezdey Behandlung von entzündungen
JP2769925B2 (ja) * 1990-10-18 1998-06-25 ミネソタ マイニング アンド マニュファクチャリング カンパニー ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
EP0518601A1 (en) * 1991-06-10 1992-12-16 Schering Corporation Non-chlorofluorocarbon aerosol formulations
ATE246497T1 (de) * 1991-06-10 2003-08-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
JP2780871B2 (ja) * 1991-06-26 1998-07-30 シェリング・コーポレーション 粉末薬剤吸入装置
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
CA2125666C (en) * 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
EP0616525B1 (en) * 1991-12-12 1995-09-27 Glaxo Group Limited Pharmaceutical aerosol formulation
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ES2099428T3 (es) * 1992-03-10 1997-05-16 Fisons Plc Composiciones farmaceuticas para inhalacion.
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Also Published As

Publication number Publication date
DK1174138T3 (da) 2011-11-21
IL112459A0 (en) 1995-03-30
SK82296A3 (en) 1997-03-05
ES2173947T3 (es) 2002-11-01
HK1041829A1 (zh) 2002-07-26
JP2008285497A (ja) 2008-11-27
FI20115742A (fi) 2011-07-08
HU9602043D0 (en) 1996-09-30
MX9602246A (es) 1997-07-31
AU1727195A (en) 1995-08-15
AU691880B2 (en) 1998-05-28
ES2368827T3 (es) 2011-11-22
EP1174139A3 (en) 2002-01-30
HU227837B1 (en) 2012-05-02
EP2156840A3 (en) 2010-05-19
ES2369516T3 (es) 2011-12-01
CN1139384A (zh) 1997-01-01
PE44995A1 (es) 1995-12-18
EP0740550B1 (en) 2002-04-17
EP0740550A1 (en) 1996-11-06
CY2616B2 (en) 2012-05-23
CZ219196A3 (en) 1996-12-11
PT1174138E (pt) 2011-10-03
CN100441192C (zh) 2008-12-10
DE69526425T2 (de) 2002-12-05
EP1174139A2 (en) 2002-01-23
MY114665A (en) 2002-12-31
NO963132L (no) 1996-09-26
EP1201242A2 (en) 2002-05-02
NO963132D0 (no) 1996-07-26
JP3480736B2 (ja) 2003-12-22
EP1192946A1 (en) 2002-04-03
EP2156840A2 (en) 2010-02-24
JP5247265B2 (ja) 2013-07-24
ATE518520T1 (de) 2011-08-15
JPH09501700A (ja) 1997-02-18
CA2182086C (en) 2000-04-11
HK1040918A1 (zh) 2002-06-28
FI123580B (fi) 2013-07-31
PL315575A1 (en) 1996-11-12
SK283338B6 (sk) 2003-06-03
CO4340692A1 (es) 1996-07-30
TW329387B (en) 1998-04-11
NO20025002L (no) 1996-09-26
HUT74884A (en) 1997-02-28
EP1174138A2 (en) 2002-01-23
CN1531967A (zh) 2004-09-29
PT740550E (pt) 2002-08-30
JPH11286447A (ja) 1999-10-19
KR100234864B1 (ko) 1999-12-15
NO328698B1 (no) 2010-04-26
HK1040911B (zh) 2011-11-18
HK1040911A1 (en) 2002-06-28
NZ279979A (en) 2001-03-30
CN100358528C (zh) 2008-01-02
EP2156840B1 (en) 2011-08-10
WO1995020393A1 (en) 1995-08-03
JP2003313128A (ja) 2003-11-06
NO20025002D0 (no) 2002-10-17
DE69526425D1 (de) 2002-05-23
ZA95637B (en) 1995-07-26
EP1201242A3 (en) 2003-12-03
FI962828A (fi) 1996-07-12
FI122395B (fi) 2011-12-30
EP1201242B1 (en) 2011-11-02
ATE519489T1 (de) 2011-08-15
ATE531364T1 (de) 2011-11-15
HK1040912A1 (zh) 2002-06-28
EP1174138A3 (en) 2002-01-30
SG47387A1 (en) 1998-04-17
DK2156840T3 (da) 2011-11-21
EP1174139B1 (en) 2011-09-21
DK0740550T3 (da) 2002-06-24
CN101164542A (zh) 2008-04-23
EP1174138B1 (en) 2011-08-03
JP2012036222A (ja) 2012-02-23
PT2156840E (pt) 2011-10-18
IL112459A (en) 1999-04-11
FI962828A0 (fi) 1996-07-12
HK1135331A1 (en) 2010-06-04
ATE525075T1 (de) 2011-10-15
CA2182086A1 (en) 1995-08-03
JP2008031184A (ja) 2008-02-14
CN101156860A (zh) 2008-04-09
NO314535B1 (no) 2003-04-07
ATE216243T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
CY2617B2 (en) Use of mometasone furoate for treating airway passage and lung diseases
PL372118A1 (en) Composition for inhalation
WO1992011025A3 (en) Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
Blanco et al. AD Loppow et al.
Heath et al. Information from your family doctor: Taking care of chronic bronchitis